Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Nanoscope received NIH support for its first-in-class delivery approach to restore vision
(Nanoscope Technologies) Researchers at Nanoscope ® Technologies, LLC are advancing development of therapeutic gene and delivery platform for treating degenerative eye diseases such as dry age-related macular degeneration (dry-AMD) which affects a significant portion of the global population. Nanoscope was just awarded a multi-million dollar grant from National Eye Institute, a division of the NIH, for advancing the spatially-targeted non-viral spatially-targeted gene delivery platform and Multi-Characteristic Opsin for AMD therapy. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 28, 2020 Category: International Medicine & Public Health Source Type: news

AI Systems Predict the Course of Macular Degeneration AI Systems Predict the Course of Macular Degeneration
Two new artificial intelligence algorithms can predict the development of age-related macular degeneration, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 27, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

AI Model Predicts Risk for Age-Related Macular Degeneration
WEDNESDAY, May 27, 2020 -- A new artificial intelligence algorithm can predict risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology. Alauddin Bhuiyan,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to those recei...
Source: Roche Investor Update - May 27, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to those recei...
Source: Roche Media News - May 27, 2020 Category: Pharmaceuticals Source Type: news

Study finds unexpected suspect in age-related macular degeneration
(eLife) Scientists have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD), according to a new study published today in eLife. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2020 Category: Biology Source Type: news

I am an eye surgeon but could soon be your doctor in the ICU. I'm terrified
I am fearful for the future, uncertain for how my skills will hold up when put to testCoronavirus – latest updatesSee all our coronavirus coverageI am an ophthalmologist. I am the doctor you see for your cataract surgery, the doctor your grandmother sees to have her age-related macular degeneration checked, the one who prescribed the bedtime drops to slow down your grandfather ’s glaucoma. In the next few weeks I will be the doctor your father sees for his stroke, the doctor who treats your grandmother’s heart failure, the doctor you see in A&E to treat your asthma. Potentially the doctor you meet in intensive ca...
Source: Guardian Unlimited Science - April 20, 2020 Category: Science Authors: Selina Khan Tags: Coronavirus outbreak Doctors Society Health Society Professionals Infectious diseases Science NHS Work & careers Guardian Careers Source Type: news

UC Riverside biochemist spins out joint venture company with Atomwise
(University of California - Riverside) Over the past few years, biochemist John Jefferson Perry at the University of California, Riverside, has collaborated on a number of projects with Atomwise Inc., a company that uses artificial intelligence for drug discovery. Now Perry and the company have formed a joint venture called Theia Biosciences. It will focus initially on helping treat age-related macular degeneration through developing small molecule inhibitors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 13, 2020 Category: International Medicine & Public Health Source Type: news

NIH researchers discover tooth-enamel protein in eyes with dry AMD
(NIH/National Eye Institute) A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), according to a study from researchers at the National Eye Institute (NEI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 13, 2020 Category: International Medicine & Public Health Source Type: news

Wireless Photovoltaic Device Restores Central Visual Sensitivity in Atrophic Age-Related Macular Degeneration Wireless Photovoltaic Device Restores Central Visual Sensitivity in Atrophic Age-Related Macular Degeneration
A wireless photovoltaic device implanted subretinally can restore central visual sensitivity in patients with geographic atrophy, an advanced form of age-related macular degeneration (AMD), according to a first-in-human clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Novartis stands by safety of eye drug amid ongoing review
Swiss drugmaker Novartis said on Monday the safety data available for its eye drug Beovu to treat wet age-related macular degeneration (wet AMD) continued to support its use as it conducts a review into the safety of the drug. (Source: Reuters: Health)
Source: Reuters: Health - March 2, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen ’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
RARITAN, NJ, March 2, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene therapy product for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). PRIME is awarded to increase interactions, optimize development plans and accelerate innovative treatments where there is unmet medical need. Similarly, ATMP status is granted to medicines that are based on genes, tiss...
Source: Johnson and Johnson - March 2, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New discovery has important implications for treating common eye disease
(Trinity College Dublin) Scientists from Trinity College Dublin have made an important discovery with implications for those living with a common, debilitating eye disease (age-related macular degeneration, AMD) that can cause blindness. They have discovered that the molecule TLR2, which recognises chemical patterns associated with infection in the body, also seems to play an important role in the development of retinal degeneration. When TLR2 is removed in model systems, a degree of protection is conferred. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 20, 2020 Category: Biology Source Type: news

Not All With AMD May Need Continuing Treatment Not All With AMD May Need Continuing Treatment
A small number of patients with neovascular age-related macular degeneration (nAMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Protein in blood may signal age-related macular degeneration, researchers say
An international team of researchers has identified a new protein that could provide a platform for improved diagnosis and treatment of age-related macular degeneration, or AMD. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 7, 2020 Category: Consumer Health News Source Type: news